Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
Get Alerts MRNS Hot Sheet
Join SI Premium – FREE
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the fourth quarter and fiscal year ended December 31, 2020 before the market opens on March 9, 2021. The company will host a conference call at 8:30am Eastern Time on March 9, 2021 to provide a business update and discuss the financial results.
Tuesday, March 9: 8:30 AM Eastern Time |
|||
Domestic: |
|
|
(833) 979-2765 |
International: |
|
|
(343) 761-2590 |
Webcast: |
|
|
https://event.on24.com/wcc/r/2948497/012AE4F51A475A8BDC3559C95635FBF2 |
Conference ID: |
|
2673136 |
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company is conducting a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005209/en/
Sasha Damouni Ellis
Vice President, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com
Source: Marinus Pharmaceuticals
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CN (CNI) Confirms 'Superior' $325/Share Bid for Kansas City Southern (KSU)
- FirstLight Launches Valley Climate Champions Program for Franklin County Teachers and Students
- Pandemic Causes Women to Have Skin Conditions Often Associated With Teenagers Says DermatologistOnCall
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!